The report "Global Hydroxychloroquine Market, By Disease Type (Coronavirus Disease (COVID-19), Malaria, Q Fever, Rheumatoid Arthritis, Lupus Erythematosus, Porphyria Cutanea Tarda (PCT), and Other Disease Types), By Distribution Channel (Specialty Drug Store, Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and By Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) - Trends, Analysis and Forecast till 2029”.
Key Highlights:
• In March 2020, Novartis announced its commitment to donate up to 130 million doses of generic hydroxychloroquine to support the global COVID-19 pandemic response. Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19. Novartis is supporting ongoing clinical trial efforts and will evaluate the needs for additional clinical trials.
• In March 2020, Mylan N.V. has ramped up its U.S. manufacturing of hydroxychloroquine sulfate tablets to meet potential COVID-19 patient needs. Mylan's hydroxychloroquine sulfate tablets are approved by the U.S. Food and Drug Administration (FDA) for the treatment of malaria, rheumatoid arthritis, and lupus erythematosus. Although the product is not currently approved for use in the treatment of COVID-19, it is listed by the World Health Organization as a drug under investigation for efficacy against the coronavirus.
Key Market Insights from the report:
The global hydroxychloroquine market accounted for US$ 1.6 billion in 2019 and is estimated to be US$ 2.7 billion by 2029 and is anticipated to register a CAGR of 5.3%. The market report has been segmented on the basis of disease type, distribution channel, and region.
• By disease type, the coronavirus disease segment is expected to register for the majority revenue share in the global hydroxychloroquine market due to growing cases of COVID-19 pandemic worldwide.
• By distribution channel, the hospital pharmacy segment is projected to witness major revenue share in the global market due to rising demand for HCQ to treat COVID-19 patients and the growing prevalence of malaria, particularly in some emerging economies.
• By region, North America followed by Canada, Mexico, and the U.S. is expected to register substantial gains by 2026. Rising coronavirus cases and a large number of clinical trials will lead to increased consumption of the product in the region, thus propelling the hydroxychloroquine market.
To know the upcoming trends and insights prevalent in this market, click the link below:
https://www.prophecymarketinsights.com/market_insight/Global-Hydroxychloroquine-Market-4319
Competitive Landscape:
The prominent player operating in the global hydroxychloroquine market includes Novartis International AG, Mylan N.V., Wallace Pharmaceuticals Ltd., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Bayer AG, Zydus Cadila Ltd., Ipca Laboratories Ltd., Cipla Limited, and Lupin Limited.
The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.
Contact Us:
Sales
Prophecy Market Insights
Email- [email protected]